U.S. Consumer Services Stock News

Concentrix (CNXC) is back in focus after Q4 results slightly topped market expectations, even as reported net losses stayed high and new guidance and GenAI recognition gave investors more to think about. See our latest analysis for Concentrix. At a share price of US$40.11, Concentrix has a 1-day share price return of 7.05% decline and a 90-day share price return of 15.24% decline. The 1-year total shareholder return of 18.64% decline and 3-year total shareholder return of 69.42% decline point...

DexCom (DXCM) has drawn investor attention after issuing preliminary revenue guidance that points to double digit growth targets for late 2025 and 2026, supported by continuous glucose monitoring adoption and the Stelo rollout. See our latest analysis for DexCom. That guidance comes after a steady recent rebound in DexCom’s shares, with a 30 day share price return of 7.07% helping lift the year to date share price return to 6.30%. This comes even as the 1 year total shareholder return sits at...

What Carlisle Companies stock performance tells you now Carlisle Companies (CSL) has been relatively steady, with the share price up around 6% over the past month and about 5% over the past 3 months, despite a 1 day decline. For longer term holders, the picture is mixed, with a 6% gain year to date but an estimated 13% total return decline over the past year, set against very large 3 year and 5 year total return multiples. See our latest analysis for Carlisle Companies. At a share price of...

Dave (NasdaqGM:DAVE) has appointed Nima Khajehnouri, Meta’s VP of Engineering, to its Board of Directors. The move brings additional AI and data engineering expertise to the company during an ongoing board reshuffle. The appointment is part of Dave’s push to deepen its technical leadership in the neobanking space. For you as an investor, this board change comes at a time when Dave’s stock has seen sharp moves. Shares recently closed at $185.27, with a 1 year return of 103.8% and a 3 year...

What Recent Returns Say About Trupanion Stock Trupanion (TRUP) has seen pressure across multiple time frames, with the share price down 3.8% over the past day, 11.8% over the past week, and 17.8% over the past month. See our latest analysis for Trupanion. That recent weakness sits on top of a tougher stretch, with the 90 day share price return of 28.4% and the 1 year total shareholder return of 34.1% both pointing to fading momentum despite the latest close at $31.22. If Trupanion’s slide has...

Earlier this week, Reliance Industries reported Q3 results that grew revenue but missed market expectations, as retail EBITDA growth slowed and margins eased while the oil and gas segment saw declines in revenue and EBITDA. Despite solid contributions from Jio Platforms and the oil-to-chemicals business, investor attention has focused on how competitive pressures and higher costs are reshaping the profitability profile of Reliance’s retail operations. Next, we’ll explore how the earnings...

RTX’s Collins Aerospace business recently signed three-year parts distribution agreements for C-130 Hercules wheels and brakes, while its Blue Canyon Technologies unit launched a satellite for NASA’s Pandora mission and, alongside Spain’s Indra Sistemas, was selected to help supply new radars under the US$12.50 billion U.S. air traffic control modernization plan. Together, these contracts highlight RTX’s reach across defense sustainment, civil aviation infrastructure and space technology,...

Fresh attention has turned to DRDGOLD (DRD) after a recent Peter Lynch style GARP screen flagged the stock for its combination of profit growth, low debt levels, and a clear focus on gold waste retreatment. See our latest analysis for DRDGOLD. At a share price of $37.66, DRDGOLD has seen strong recent momentum, with a 20.55% 1 month share price return and a 49.44% 3 month share price return contributing to a very large 1 year total shareholder return. This suggests that investors may be...

Why Erie Indemnity (ERIE) is on investors’ radar now Erie Indemnity (ERIE) has drawn fresh attention after recent price moves, with a 1 day return of about 1.3% and a modest gain over the past month, contrasting with weaker performance over the past 3 months. For investors tracking consistency, that mixed return profile sits alongside reported annual revenue of about US$4.0b and net income of roughly US$648m. Revenue and earnings growth figures are also available for closer review. See our...

If you are trying to work out whether NextDecade's current share price still reflects its long term potential, the key question is how the stock stacks up against its underlying value. The share price closed at US$4.86 recently, after a 7.4% decline over the last week and a 11.3% decline over the last month, with the one year return at a 46.3% loss and the five year return at 78.7%. Recent news around NextDecade has focused on its role in US liquefied natural gas projects and its efforts to...

If you are wondering whether SLM's share price still reflects good value after its long run as a student lending name, you are not alone. The stock last closed at US$26.00, with returns of a 3.1% decline over 7 days, a 4.9% decline over 30 days, a 5.1% decline year to date, and a 7.4% decline over 1 year. The 3 year and 5 year returns sit at 65.1% and 120.9% respectively. Recent coverage has focused on how SLM fits into the broader student loan and consumer credit conversation, with...

Earlier this month, Freshworks Inc. appointed Kady Srinivasan as Chief Marketing Officer, adding a leader with more than 15 years of SaaS marketing experience to oversee its global marketing strategy under Chief Integrated Customer Growth Officer Mika Yamamoto. Srinivasan’s background in scaling software businesses, improving marketing efficiency, and advising AI-focused startups underlines Freshworks’ emphasis on sharpening its go-to-market engine and AI-driven product positioning. Next,...

Crown Castle (CCI) is in focus after DISH Wireless defaulted on payment obligations, prompting Crown Castle to terminate their wireless infrastructure agreement. This material contract change is now being reassessed by several Wall Street firms. See our latest analysis for Crown Castle. The contract termination headlines coincide with a sharp 4.47% one-day share price decline to US$86.81. Over 90 days, the share price has fallen 11.15%, which contrasts with a slightly positive 1-year total...

Recent share performance snapshot With no fresh company specific headlines driving Harley-Davidson (HOG) today, the focus for investors is on the stock’s recent performance and fundamentals, including returns, revenue, earnings and its diversified business segments. See our latest analysis for Harley-Davidson. At a share price of US$20.10, Harley-Davidson’s recent 1 day, 7 day and 30 day share price returns show steady declines, and the 1 year and 5 year total shareholder returns indicate...

Apellis Pharmaceuticals recently secured US FDA approval for EMPAVELI to treat the rare kidney diseases C3 glomerulopathy and IC-MPGN, the first and only approved therapy for these conditions, while facing slower-than-hoped patient uptake and flat SYFOVRE sales due to access and reimbursement hurdles. This combination of a major regulatory win with muted early commercial traction highlights the tension between scientific success and the practical realities of rare-disease drug...

Edgewise Therapeutics (EWTX) updated investors on its late stage pipeline, outlining 2026 milestones for muscular dystrophy and cardiovascular programs. These include key sevasemten trial readouts and a potential future New Drug Application submission. See our latest analysis for Edgewise Therapeutics. The update on 2026 clinical milestones comes as Edgewise Therapeutics trades at $28.73, with a 90 day share price return of 92.95% and a 3 year total shareholder return of 160.24%. This...

Invesco’s S&P 500 Equal Weight ETF (RSP) and QQQ Trust are being compared with rival ETFs from Vanguard and iShares, with a focus on portfolio construction and sector diversification. These comparisons examine how equal weight and Nasdaq focused products from Invesco stack up against more traditional market cap weighted options. The recent discussions highlight differences in risk profile, concentration, and potential role in investor portfolios. For investors watching NYSE:IVZ, this...

Why Amneal Pharmaceuticals Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has attracted fresh attention after recent share price moves, with the stock showing a 0.6% decline over the last day but gains over the past week, month, and past 3 months. See our latest analysis for Amneal Pharmaceuticals. That recent pullback comes after a strong run, with a 27.8% 90 day share price return and a very large 3 year total shareholder return. Together, these point to momentum that has attracted...

Klarna Group (NYSE:KLAR) is facing multiple securities class action lawsuits tied to its IPO, focused on alleged misstatements about credit risks and loss provisions. At the same time, Klarna is expanding its partnership with OnePay to introduce a new Swipe to Finance flexible payment feature. The company has also rolled out instant peer to peer payments across 13 European countries as it deepens its push into digital banking. For you as an investor, this combination of legal scrutiny and...

In January 2026, Axogen, Inc. issued preliminary unaudited guidance indicating expected fourth-quarter 2025 revenue of about US$59.9 million and full-year 2025 revenue of about US$225.2 million, both reflecting strong year-over-year growth versus 2024. This guidance highlights broad strength across Axogen’s product portfolio, suggesting that demand is increasing across multiple areas of its nerve repair business. Next, we’ll examine how Axogen’s projected full-year 2025 revenue of about...

In January 2026, Progressive Insurance expanded its portfolio by launching a new directly underwritten pet insurance product, administered by Companion Protect and offering customizable Accident and Illness coverage plus optional Wellness benefits across 43 states and D.C. This move deepens Progressive’s presence in the pet protection space, leveraging its long history in pet-related coverage while adding digital claims servicing, vet expert access, and multi-pet and bundling...

If you are wondering whether VeriSign's share price still reflects fair value or if expectations have run ahead of the fundamentals, you are in the right place. VeriSign shares most recently closed at US$248.12, with returns of 0.7% over the last 7 days, 1.7% over the last 30 days, 3.2% year to date and 18.9% over 1 year, while the 3 and 5 year returns sit at 16.1% and 27.7% respectively. These price moves sit against a backdrop of ongoing attention on domain infrastructure providers and the...

In recent days, multiple top analysts reiterated positive views on monday.com, emphasizing its mission-critical work management platform, strong gross margins, and profitability. Alongside reaffirmed confidence, analysts highlighted monday.com’s expansion into marketing, developer, and IT support solutions, broadening the role its software can play for customers. Next, we’ll explore how this wave of analyst optimism around monday.com’s profitability and product expansion shapes its...

If you are wondering whether Paycom Software's current share price lines up with its underlying value, you are not alone. This article is built to help you size that up clearly. The stock closed at US$147.48, with returns of a 6.4% decline over 7 days, a 9.4% decline over 30 days, a 3.2% decline year to date and a 29.0% decline over 1 year, alongside a 53.0% decline over 3 years and a 61.6% decline over 5 years, which may have shifted how investors view its risk and potential reward. Recent...